MX2021010046A - Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. - Google Patents

Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.

Info

Publication number
MX2021010046A
MX2021010046A MX2021010046A MX2021010046A MX2021010046A MX 2021010046 A MX2021010046 A MX 2021010046A MX 2021010046 A MX2021010046 A MX 2021010046A MX 2021010046 A MX2021010046 A MX 2021010046A MX 2021010046 A MX2021010046 A MX 2021010046A
Authority
MX
Mexico
Prior art keywords
composition containing
active ingredient
containing apomorphine
therapeutical composition
new therapeutical
Prior art date
Application number
MX2021010046A
Other languages
English (en)
Inventor
Joel Richard
Jeremiah Harnett
Nathalie Mondoly
Laurent Bertocchi
Michael Dey
Marie - Madeleine BARONNET
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of MX2021010046A publication Critical patent/MX2021010046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

La presente invención se refiere a una composición farmacéutica que contiene apomorfina como principio farmacéutico activo, codisolvente, antioxidante, agua con un pH mayor que 4. La formulación farmacéutica es adecuada para la administración parenteral para el tratamiento de la enfermedad de Parkinson.
MX2021010046A 2011-07-11 2014-01-10 Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. MX2021010046A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11290320A EP2545905A1 (en) 2011-07-11 2011-07-11 A new therapeutical composition containing apomorphine as active ingredient

Publications (1)

Publication Number Publication Date
MX2021010046A true MX2021010046A (es) 2021-09-21

Family

ID=46514305

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000454A MX2014000454A (es) 2011-07-11 2012-07-11 Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
MX2021010046A MX2021010046A (es) 2011-07-11 2014-01-10 Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014000454A MX2014000454A (es) 2011-07-11 2012-07-11 Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.

Country Status (29)

Country Link
US (4) US11026938B2 (es)
EP (2) EP2545905A1 (es)
JP (2) JP6356064B2 (es)
KR (1) KR101990897B1 (es)
CN (2) CN103826612B (es)
AU (1) AU2012283381B2 (es)
BR (1) BR112014000306B1 (es)
CA (1) CA2841807C (es)
CL (1) CL2014000050A1 (es)
CO (1) CO6870038A2 (es)
CR (1) CR20140005A (es)
CU (1) CU24159B1 (es)
DO (1) DOP2014000003A (es)
EA (1) EA025870B1 (es)
EC (1) ECSP14013200A (es)
GE (1) GEP20196969B (es)
GT (1) GT201400003A (es)
IL (1) IL230308A (es)
IN (1) IN2014DN00090A (es)
MA (1) MA35411B1 (es)
MX (2) MX2014000454A (es)
MY (1) MY168212A (es)
NI (1) NI201400003A (es)
PE (1) PE20141539A1 (es)
SG (1) SG10201605491PA (es)
TN (1) TN2014000001A1 (es)
UA (1) UA113962C2 (es)
WO (1) WO2013007381A1 (es)
ZA (1) ZA201309711B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
EP2854764B1 (en) * 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
CA2971826A1 (en) * 2014-12-23 2016-06-30 Neuroderm Ltd Crystal forms of apomorphine and uses thereof
AU2016333486B2 (en) * 2015-09-28 2022-02-03 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
US20220249465A1 (en) * 2019-05-31 2022-08-11 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
JP2022543803A (ja) * 2019-08-07 2022-10-14 アクリプス ワン インコーポレイテッド （６ａＳ）－６－メチル－５，６，６ａ，７－テトラヒドロ－４Ｈ－ジベンゾ［ｄｅ，ｇ］キノリン－１０，１１－ジオールの医薬組成物
EP4154885A1 (en) 2020-05-20 2023-03-29 MEDRx Co., Ltd. Apomorphine-containing percutaneous absorption type preparation
WO2022271537A1 (en) * 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1662566A1 (ru) * 1988-03-05 1991-07-15 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ стабилизации инъекционного раствора апоморфина
JP2822049B2 (ja) * 1989-02-02 1998-11-05 ゼリア新薬工業株式会社 水性製剤組成物
ES2239369T3 (es) * 1993-03-26 2005-09-16 Franciscus Wilhelmus Henricus Maria Merkus Composiciones farmaceuticas para administracion intranasal de dihidroergotamina.
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6011043A (en) 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US20030008878A1 (en) 2001-03-09 2003-01-09 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
ITMI20011321A1 (it) * 2001-06-22 2002-12-22 Chiesi Farma Spa Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US6939094B2 (en) 2003-01-28 2005-09-06 Macro Technologies Inc. Autonomous power interface for modifying limited rotation speed of a machine
WO2004089988A2 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
EP1714648A4 (en) * 2004-02-09 2010-05-26 Aska Pharm Co Ltd COMBINATION DRUGS
CA2652886A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity
US20080171072A1 (en) * 2006-08-11 2008-07-17 Frank Burczynski Ocular inserts containing apomorphine
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
CN101712675B (zh) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient

Also Published As

Publication number Publication date
NI201400003A (es) 2015-10-12
WO2013007381A1 (en) 2013-01-17
UA113962C2 (xx) 2017-04-10
CR20140005A (es) 2014-07-21
US20160310480A1 (en) 2016-10-27
MA35411B1 (fr) 2014-09-01
CL2014000050A1 (es) 2014-08-18
US11766431B2 (en) 2023-09-26
CA2841807A1 (en) 2013-01-17
DOP2014000003A (es) 2014-06-01
CO6870038A2 (es) 2014-02-20
KR20140072861A (ko) 2014-06-13
CN103826612B (zh) 2020-07-28
BR112014000306B1 (pt) 2022-03-29
US11026938B2 (en) 2021-06-08
MY168212A (en) 2018-10-15
CU24159B1 (es) 2016-03-31
CU20140005A7 (es) 2014-04-24
CN108434094A (zh) 2018-08-24
US20210244724A1 (en) 2021-08-12
TN2014000001A1 (en) 2015-07-01
IN2014DN00090A (es) 2015-05-15
CA2841807C (en) 2018-02-20
CN103826612A (zh) 2014-05-28
ECSP14013200A (es) 2014-04-30
JP6356064B2 (ja) 2018-07-11
EA025870B1 (ru) 2017-02-28
MX2014000454A (es) 2014-09-01
JP2017081947A (ja) 2017-05-18
EP2731589A1 (en) 2014-05-21
GT201400003A (es) 2017-09-28
AU2012283381B2 (en) 2017-07-27
IL230308A (en) 2017-04-30
SG10201605491PA (en) 2016-08-30
EA201400067A1 (ru) 2015-02-27
US20140128422A1 (en) 2014-05-08
JP2014518285A (ja) 2014-07-28
AU2012283381A1 (en) 2014-02-06
GEP20196969B (en) 2019-04-25
ZA201309711B (en) 2014-08-27
BR112014000306A2 (pt) 2017-02-07
US20180098981A1 (en) 2018-04-12
PE20141539A1 (es) 2014-10-25
KR101990897B1 (ko) 2019-06-19
EP2545905A1 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
NZ608116A (en) Triazine-oxadiazoles
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
WO2013061205A3 (en) (4 - phenylimidazol - 2 - yl) ethylamine derivatives usful as sodium channel modulators
MA37866A1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
MX2013012588A (es) Inhibidores de cinasa.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
NZ607580A (en) N-heteroaryl compounds
IN2012DN02502A (es)
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX364400B (es) Compuestos de tetraciclina.
IN2014DN05972A (es)
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
EA201490573A1 (ru) Соединение бензотиазолона
IN2013DN02555A (es)
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
IN2014MN02433A (es)
WO2013043744A3 (en) Tricyclic compounds useful as neurogenic and neuroprotective agents
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
WO2011140682A8 (zh) （2e）-3-苯基-n-[2，2，2-三氯-1-[[（8-喹啉基氨基）硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途
NZ700507A (en) Pyrimidine derivatives for the treatment of bacterial diseases